Table 1.
Results for placebo treatments in the studies included in the meta-analysis.
| Author, date [reference] | Placebo | Duration (wks) | Mean micturitions/day | Mean incontinence episodes/day | Mean volume voided per micturition (mL) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| n | BL | EOT | CFBL | BL | EOT | CFBL | BL | EOT | CFBL | ||
| Abrams, 1998 [11] | 57 | 12 | 11.7 | NR | -1.6 | 3.3 | NR | -0.9 | 157 | NR | 6 |
| Burgio, 1998 [12] | 65 | 8 | NR | NR | NR | 2.2 | 1.2 | -1.03 | NR | NR | NR |
| Cardozo, 2004 [13] | 301 | 12 | NR | NR | -1.59 | NR | NR | -1.25 | NR | NR | 10.67 |
| Chapple, 2004 [14] | 38 | 4 | 11.1 | 10.1 | -1.03 | 1.7 | 1.4 | -0.29 | 134.7 | 144.4 | 9.7 |
| Chapple, 2004 [15] | 267 | 12 | 12.2 | 11 | -1.2 | 2.7 | 2 | -0.76 | 143.8 | 151.2 | 7.4 |
| Chapple, 2007 [16] | 285 | 12 | 12 | 10.9 | -1.02 | 3.7 | 2.5 | -1.2 | 150.2 | 159.9 | 9.77 |
| Dmochowski, 2002 [17] | 132 | 12 | NR | NR | -1.7 | NR | NR | NR | NR | NR | NR |
| Dmochowski, 2003 [18] | 117 | 12 | 12.3 | 10.9 | -1.4 | 5 | 2.9 | -2.1 | 175 | 182 | 9 |
| Dmochowski, 2008 [9] | 284 | 12 | 12.9 | 11.1 | -1.8 | 4 | 2.4 | -1.6 | 151.8 | 169.6 | 17.8 |
| Dorschner, 2003 [19] | 49 | 4 | 7.1 | 6.5 | -0.6 | 0.4 | 0.2 | -0.1 | 187 | 178 | -8.4 |
| Drutz, 1999 [20] | 56 | 12 | 11.4 | 10.3 | -1.1 | 3.6 | 2.6 | -1 | 160 | 172 | 12 |
| Halaska, 1994 [21] | 47 | 4 | NR | NR | NR | NR | NR | NR | 195 | 221 | 26 |
| Herschorn, 2007 [22] | 204 | 12 | 11.8 | 10.1 | -1.7 | 3.2 | 1.8 | -1.4 | NR | NR | NR |
| Homma, 2003 [23] | 122 | 12 | 11.1 | 9.6 | -1.5 | 2.7 | 1.6 | -1.09 | 130.7 | 145.8 | 15.2 |
| Jacquetin, 2001 [24] | 51 | 4 | 11.7 | 10.5 | -1.2 | 2.4 | NR | -0.4 | 148 | 155 | 7 |
| Junemann, 2000 [25] | 60 | 3 | NR | NR | -1.9 | NR | NR | NR | NR | NR | NR |
| Junemann, 2006 [26] | 202 | 4.57 | 13.4 | 10.3 | -3.07 | 3.5 | 1.7 | -1.78 | 144.2 | 173.5 | 29.3 |
| Khullar, 2004 [27] | 285 | 8 | 10.6 | 9.3 | -1.3 | 3.1 | NR | -1.14 | 167 | 185.9 | 18.9 |
| Lee 2006, [28] | 79 | 12 | 13 | 10.4 | -2.58 | NR | NR | NR | NR | NR | NR |
| Madersbacher, 1999 [29] | 72 | 4 | 11.5 | 10.5 | -1 | NR | NR | NR | NR | NR | NR |
| Malone-Lee, 2001 [30] | 43 | 4 | 9.9 | 10.3 | 0.4 | 5.1 | 4.4 | -0.7 | 152 | 162 | 10 |
| Malone-Lee, 2002 [31] | 73 | 12 | NR | NR | NR | NR | NR | NR | NR | NR | 15.91 |
| Millard, 1999 [32] | 64 | 12 | 11.3 | 9.9 | -1.4 | 3.5 | 2.2 | -1.3 | 158 | 168 | 10 |
| Nitti, 2007 [33] | 274 | 12 | 12.2 | 11.1 | -1.08 | 3.7 | 2.7 | -0.96 | 159 | 167.4 | 8.38 |
| Rackley, 2006 [34] | 421 | 12 | 12.6 | NR | NR | 0.72 | NR | NR | 140.1 | NR | NR |
| Rentzhog, 1998 [35] | 13 | 2 | 10.2 | NR | -0.3 | 4.1 | NR | -0.4 | NR | NR | NR |
| Robinson, 2007 [36] | 61 | 6 | 11.9 | 10.1 | -1.81 | 2.9 | 2.2 | -0.66 | 145.5 | 156.9 | 11.4 |
| Rogers, 2008 [37] | 211 | 12 | 12.5 | 10.3 | -2.2 | 2.2 | 0.8 | -1.3 | NR | NR | NR |
| Rudy, 2006 [38] | 329 | 12 | 13.2 | 11.4 | -1.76 | NR | NR | NR | 154.6 | 164.1 | 9.44 |
| Staskin, 2007 [10] | 303 | 12 | 12.7 | 10.8 | -1.99 | 4.1 | 2.2 | -1.93 | 155.9 | 174.8 | 18.89 |
| Thuroff, 1991 [39] | 27 | 4 | NR | NR | -0.3 | NR | NR | NR | NR | NR | NR |
| Uchida, 2002 [40] | 53 | 4 | 10.9 | 9.9 | -1 | 2.3 | 1 | -1.3 | 196 | 202 | 6 |
| van Kerrebroeck, 2001 [41] | 508 | 12 | 11.3 | 9.1 | -2.2 | 3.3 | 2.3 | -0.99 | 136 | 150 | 14 |
| Wang, 2006 [42] | 21 | 12 | NR | NR | NR | NR | NR | NR | 350 | 340 | 10 |
| Yamaguchi, 2007 [43] | 405 | 12 | 11.4 | 10.3 | -0.94 | 2 | 1.3 | -0.72 | 152.8 | 164.5 | 11.67 |
| Zinner, 2004 [44] | 256 | 12 | 12.9 | 11.6 | -1.29 | 4.3 | 2.4 | -1.9 | 156.6 | 164.3 | 7.7 |
BL: Baseline
EOT: End of treatment
CFBL: Change from baseline
NR: Not reported